{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:38:44Z","timestamp":1793831924250,"version":"4.6.1"},"reference-count":66,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Significant advancements have been made in the management of obstructive hypertrophic cardiomyopathy (oHCM), yet the extent of left ventricular outflow tract (LVOT) gradient reduction achieved with commonly used pharmacological therapies [beta-blockers (BBs), calcium channel blockers (CCBs), disopyramide, and cardiac myosin inhibitors (CMIs)] relative to each other is still unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>PubMed and Scopus were searched up to September 2024. Clinical trials or observational studies that assessed the changes associated with BBs, CCBs, disopyramide, or CMIs in LVOT gradient at rest or with provocation in patients with oHCM were included. Mean changes in LVOT gradients were pooled as mean differences (MD) with 95% confidence intervals (CIs) in a random-effects model. Thirty-seven studies, with 44 arms and 1898 patients, were included in the analysis. At the therapeutic class level, pooled analysis showed that disopyramide was associated with the highest reduction in LVOT gradient at rest [MD: \u221243.5 (95% CI, \u221251.6 to \u221235.3)], followed by CMIs [MD: \u221234.8 (95% CI, \u221240.6 to \u221229.0)], BBs [MD: \u221220.7 (95% CI, \u221229.4 to \u221212.0)], and then CCBs [MD: \u221214.7 (95% CI, \u221223.3 to \u22126.1)], inter-action P &amp;lt; 0.01. Within CMIs, mavacamten had a higher effect than aficamten on gradient reduction; among the included BBs, metoprolol showed the highest gradient reduction, while among CCBs, verapamil was the most effective (inter-action P &amp;lt; 0.01). Similar results were observed for provocable LVOT gradients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pharmacological therapies effectively reduced LVOT gradients in oHCM patients to varying degrees, with disopyramide and CMIs showing the highest effect, followed by BBs and CCBs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvaf036","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T06:20:07Z","timestamp":1747376407000},"page":"469-482","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy of pharmacological therapies in reducing outflow tract obstruction in patients with obstructive hypertrophic cardiomyopathy: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"11","author":[{"given":"Kamal","family":"Awad","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , 5777 E Mayo Blvd, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milagros","family":"Pereyra Pietri","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , 5777 E Mayo Blvd, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan M","family":"Farina","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , 5777 E Mayo Blvd, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish","family":"Pathangey","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , 5777 E Mayo Blvd, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Tiseer","family":"Abbas","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , 5777 E Mayo Blvd, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel G","family":"Scalia","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , 5777 E Mayo Blvd, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4227-5817","authenticated-orcid":false,"given":"David","family":"Le Couteur","sequence":"additional","affiliation":[{"name":"ANZAC Research Institute, Concord Hospital , Hospital Road, Concord, NSW 2139, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Wilanksy","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , 5777 E Mayo Blvd, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J","family":"Lester","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , 5777 E Mayo Blvd, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve R","family":"Ommen","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , 200 First St. SW, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1671-4262","authenticated-orcid":false,"given":"Jeffrey B","family":"Geske","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , 200 First St. SW, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Arsanjani","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , 5777 E Mayo Blvd, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5877-7478","authenticated-orcid":false,"given":"Chadi","family":"Ayoub","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , 5777 E Mayo Blvd, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"2025081219532729600_pvaf036-B1","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.jacc.2020.08.045","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"76","author":"Ommen","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2025081219532729600_pvaf036-B2","doi-asserted-by":"crossref","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology joint committee on clinical practice guidelines","volume":"149","author":"Ommen","year":"2024","journal-title":"Circulation"},{"key":"2025081219532729600_pvaf036-B3","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.amjcard.2017.08.047","article-title":"Comparison of valsalva maneuver, amyl nitrite, and exercise echocardiography to demonstrate latent left ventricular outflow obstruction in hypertrophic cardiomyopathy","volume":"120","author":"Ayoub","year":"2017","journal-title":"Am J Cardiol"},{"key":"2025081219532729600_pvaf036-B4","first-page":"e123","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"3","author":"Moher","year":"2009","journal-title":"Open Med"},{"key":"2025081219532729600_pvaf036-B5","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jcin.2012.01.026","article-title":"Assessment of left ventricular outflow gradient: hypertrophic cardiomyopathy versus aortic valvular stenosis","volume":"5","author":"Geske","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"key":"2025081219532729600_pvaf036-B6","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1378\/chest.83.4.704","article-title":"Adverse effects of nifedipine therapy on hypertrophic obstructive cardiomyopathy","volume":"83","author":"Fedor","year":"1983","journal-title":"Chest"},{"key":"2025081219532729600_pvaf036-B7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/BF00609854","article-title":"Adverse reactions to practolol in hospitalized patients: a report from the Boston collaborative drug surveillance program","volume":"12","author":"Pfeifer","year":"1977","journal-title":"Eur J Clin Pharmacol"},{"key":"2025081219532729600_pvaf036-B8","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2025081219532729600_pvaf036-B9","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2025081219532729600_pvaf036-B10","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0895-4356(92)90054-Q","article-title":"Variance imputation for overviews of clinical trials with continuous response","volume":"45","author":"Follmann","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"2025081219532729600_pvaf036-B11"},{"key":"2025081219532729600_pvaf036-B12","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"2025081219532729600_pvaf036-B13","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1136\/bmj.331.7521.903","article-title":"Standard deviations and standard errors","volume":"331","author":"Altman","year":"2005","journal-title":"BMJ"},{"key":"2025081219532729600_pvaf036-B14","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.cegh.2018.05.005","article-title":"Interpretation of subgroup analyses in systematic reviews: a tutorial","volume":"7","author":"Richardson","year":"2019","journal-title":"Clin Epidemiol Glob"},{"key":"2025081219532729600_pvaf036-B15","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"2025081219532729600_pvaf036-B16","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijcard.2022.03.013","article-title":"Bisoprolol for treatment of symptomatic patients with obstructive hypertrophic cardiomyopathy. The BASIC (bisoprolol AS therapy in hypertrophic cardiomyopathy) study","volume":"354","author":"Monda","year":"2022","journal-title":"Int J Cardiol"},{"key":"2025081219532729600_pvaf036-B17","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/j.jacc.2021.07.065","article-title":"Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy.","volume":"78","author":"Dybro","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2025081219532729600_pvaf036-B18","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/s00380-014-0534-3","article-title":"Effects of flecainide on left ventricular pressure gradient and symptoms in obstructive hypertrophic cardiomyopathy: a comparison of flecainide and disopyramide","volume":"30","author":"Haruki","year":"2015","journal-title":"Heart Vessels"},{"key":"2025081219532729600_pvaf036-B19","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1161\/CIRCHEARTFAILURE.112.000122","article-title":"Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with beta-blockade or verapamil","volume":"6","author":"Sherrid","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2025081219532729600_pvaf036-B20","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.amjcard.2012.04.051","article-title":"Beta blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy","volume":"110","author":"Nistri","year":"2012","journal-title":"Am J Cardiol"},{"key":"2025081219532729600_pvaf036-B21","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.amjcard.2010.06.059","article-title":"Comparison of acute reduction in left ventricular outflow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus pilsicainide versus cibenzoline","volume":"106","author":"Kajimoto","year":"2010","journal-title":"Am J Cardiol"},{"key":"2025081219532729600_pvaf036-B22","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jacc.2005.01.012","article-title":"Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Sherrid","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2025081219532729600_pvaf036-B23","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0002-9149(96)00336-0","article-title":"Effects of diltiazem on left ventricular systolic and diastolic function in hypertrophic cardiomyopathy","volume":"78","author":"Betocchi","year":"1996","journal-title":"Am J Cardiol"},{"key":"2025081219532729600_pvaf036-B24","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/0735-1097(95)00229-W","article-title":"Salutary effect of disopyramide on left ventricular diastolic function in hypertrophic obstructive cardiomyopathy","volume":"26","author":"Matsubara","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"2025081219532729600_pvaf036-B25","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/0002-8703(93)90760-7","article-title":"Acute dose-response effects of intravenous disopyramide in hypertrophic obstructive cardiomyopathy.","volume":"125","author":"Kimball","year":"1993","journal-title":"Am Heart J"},{"key":"2025081219532729600_pvaf036-B26","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0002-9149(93)90797-G","article-title":"Effects on left ventricular function of pindolol added to verapamil in hypertrophic cardiomyopathy","volume":"71","author":"Dimitrow","year":"1993","journal-title":"Am J Cardiol"},{"key":"2025081219532729600_pvaf036-B27","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/0002-9149(92)90249-X","article-title":"Efficiency of disopyramide in hypertrophic cardiomyopathy during stress states","volume":"69","author":"Millaire","year":"1992","journal-title":"Am J Cardiol"},{"key":"2025081219532729600_pvaf036-B28","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/0002-9149(88)90268-8","article-title":"Disopyramide in hypertrophic cardiomyopathy. I. Hemodynamic assessment after intravenous administration","volume":"62","author":"Pollick","year":"1988","journal-title":"Am J Cardiol"},{"key":"2025081219532729600_pvaf036-B29","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/0002-9149(88)90269-X","article-title":"Disopyramide in hypertrophic cardiomyopathy. II. Noninvasive assessment after oral administration.","volume":"62","author":"Pollick","year":"1988","journal-title":"Am J Cardiol"},{"key":"2025081219532729600_pvaf036-B30","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/0002-9149(88)90553-X","article-title":"Oral disopyramide therapy for obstructive hypertrophic cardiomyopathy","volume":"62","author":"Sherrid","year":"1988","journal-title":"Am J Cardiol"},{"key":"2025081219532729600_pvaf036-B31","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1136\/hrt.51.5.523","article-title":"Hypertrophic obstructive cardiomyopathy. Effects of acute and chronic verapamil treatment on left ventricular systolic and diastolic function","volume":"51","author":"Anderson","year":"1984","journal-title":"Br Heart J"},{"issue":"5","key":"2025081219532729600_pvaf036-B32","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1161\/01.CIR.68.5.1062","article-title":"Effects of verapamil on left ventricular systolic and diastolic function in patients with hypertrophic cardiomyopathy: pressure-volume analysis with a nonimaging scintillation probe","volume":"68","author":"Bonow","year":"1983","journal-title":"Circulation"},{"key":"2025081219532729600_pvaf036-B33","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1378\/chest.84.1.54","article-title":"Left ventricular end-diastolic pressure-volume relationships in hypertrophic cardiomyopathy. Changes induced by verapamil","volume":"84","author":"Tendera","year":"1983","journal-title":"Chest"},{"key":"2025081219532729600_pvaf036-B34","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/hrt.48.1.19","article-title":"Haemodynamic effects of nifedipine and propranolol in patients with hypertrophic obstructive cardiomyopathy","volume":"48","author":"Landmark","year":"1982","journal-title":"Br Heart J"},{"key":"2025081219532729600_pvaf036-B35","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJM198210143071607","article-title":"Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide","volume":"307","author":"Pollick","year":"1982","journal-title":"N Engl J Med"},{"key":"2025081219532729600_pvaf036-B36","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/oxfordjournals.eurheartj.a061210","article-title":"Hemodynamic effects of strophanthin and pindolol in patients with hypertrophic cardiomyopathy","volume":"2","author":"Storstein","year":"1981","journal-title":"Eur Heart J"},{"key":"2025081219532729600_pvaf036-B37","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/hrt.42.1.35","article-title":"Treatment of hypertrophic obstructive cardiomyopathy with verapamil","volume":"42","author":"Kaltenbach","year":"1979","journal-title":"Br Heart J"},{"key":"2025081219532729600_pvaf036-B38","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1161\/01.CIR.60.6.1201","article-title":"Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects","volume":"60","author":"Rosing","year":"1979","journal-title":"Circulation"},{"key":"2025081219532729600_pvaf036-B39","doi-asserted-by":"crossref","first-page":"1416600","DOI":"10.3389\/fcvm.2024.1416600","article-title":"Long-term follow-up study on obstructive hypertrophic cardiomyopathy patients treated with disopyramide: evidences of a notable trend in symptom control within a real-world clinical setting","volume":"11","author":"Todde","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"2025081219532729600_pvaf036-B40","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/ehf2.14882","article-title":"Mavacamten in real-life practice: Initial experience at a hypertrophic cardiomyopathy centre","volume":"12","author":"Abood","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2025081219532729600_pvaf036-B41","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.pcad.2024.02.001","article-title":"Real-world experience with mavacamten in obstructive hypertrophic cardiomyopathy: Observations from a tertiary care center","volume":"86","author":"Desai","year":"2024","journal-title":"Prog Cardiovasc Dis"},{"key":"2025081219532729600_pvaf036-B42","doi-asserted-by":"crossref","first-page":"e034069","DOI":"10.1161\/JAHA.123.034069","article-title":"Eighteen-Month real-world experience using mavacamten for treatment of obstructive hypertrophic cardiomyopathy in a racially diverse population","volume":"13","author":"Ramonfaur","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"2025081219532729600_pvaf036-B43","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jchf.2024.03.009","article-title":"Real-World experience and 36-week outcomes of patients with symptomatic obstructive hypertrophic cardiomyopathy treated with mavacamten","volume":"12","author":"Reza","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2025081219532729600_pvaf036-B44","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.pcad.2024.05.008","article-title":"Predictors of short-term and long-term effects of mavacamten in obstructive hypertrophic cardiomyopathy","volume":"86","author":"Roehl","year":"2024","journal-title":"Prog Cardiovasc Dis"},{"key":"2025081219532729600_pvaf036-B45","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.jcmg.2023.06.008","article-title":"Early observations on effects of mavacamten on left atrial function in obstructive hypertrophic cardiomyopathy patients","volume":"16","author":"Wessly","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"2025081219532729600_pvaf036-B46","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/jamacardio.2023.3030","article-title":"Effect of mavacamten on Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: The EXPLORER-CN randomized clinical trial","volume":"8","author":"Tian","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2025081219532729600_pvaf036-B47","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"2025081219532729600_pvaf036-B48","doi-asserted-by":"crossref","first-page":"741","DOI":"10.7326\/M18-3016","article-title":"Mavacamten treatment for obstructive hypertrophic cardiomyopathy: A clinical trial","volume":"170","author":"Heitner","year":"2019","journal-title":"Ann Intern Med"},{"key":"2025081219532729600_pvaf036-B49","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2025081219532729600_pvaf036-B50","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten for symptomatic obstructive hypertrophic cardiomyopathy","volume":"390","author":"Maron","year":"2024","journal-title":"N Engl J Med"},{"key":"2025081219532729600_pvaf036-B51","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","article-title":"Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy","volume":"81","author":"Maron","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2025081219532729600_pvaf036-B52","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.cardfail.2023.07.003","article-title":"Aficamten for drug-refractory severe obstructive hypertrophic cardiomyopathy in patients receiving disopyramide: REDWOOD-HCM cohort 3","volume":"29","author":"Owens","year":"2023","journal-title":"J Card Fail"},{"key":"2025081219532729600_pvaf036-B53","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.amjcard.2023.10.059","article-title":"The efficacy of cardiac myosin inhibitors versus placebo in patients with symptomatic hypertrophic cardiomyopathy: a meta-analysis and systematic review","volume":"210","author":"Yassen","year":"2024","journal-title":"Am J Cardiol"},{"key":"2025081219532729600_pvaf036-B54","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ehf2.14142","article-title":"Current therapies for hypertrophic cardiomyopathy: a systematic review and meta-analysis of the literature","volume":"10","author":"Bayonas-Ruiz","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2025081219532729600_pvaf036-B55","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.jacc.2024.02.014","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology joint committee on clinical practice Guidelines","volume":"83","author":"Writing Committee","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2025081219532729600_pvaf036-B56","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies: developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC)","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"2025081219532729600_pvaf036-B57","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.amjmed.2019.01.039","article-title":"Misconceptions and facts about Beta-blockers","volume":"132","author":"Argulian","year":"2019","journal-title":"Am J Med"},{"key":"2025081219532729600_pvaf036-B58","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1161\/CIRCULATIONAHA.122.062534","article-title":"Dose-blinded myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy: outcomes through 32 weeks","volume":"147","author":"Desai","year":"2023","journal-title":"Circulation"},{"key":"2025081219532729600_pvaf036-B59","first-page":"369","article-title":"Mavacamten for hypertrophic cardiomyopathy: effectiveness and value","volume":"28","author":"Beinfeld","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"key":"2025081219532729600_pvaf036-B60","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.cjco.2024.03.006","article-title":"Does disopyramide still have a place in the management of obstructive hypertrophic cardiomyopathy?","volume":"6","author":"Corriveau","year":"2024","journal-title":"CJC Open"},{"key":"2025081219532729600_pvaf036-B61","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s40256-023-00599-0","article-title":"Aficamten: a breakthrough therapy for symptomatic obstructive hypertrophic cardiomyopathy","volume":"23","author":"Sebastian","year":"2023","journal-title":"Am J Cardiovasc Drugs"},{"key":"2025081219532729600_pvaf036-B62","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.jchf.2023.04.018","article-title":"Cardiac myosin inhibitors for managing obstructive hypertrophic cardiomyopathy: JACC: heart failure state-of-the-art review","volume":"11","author":"Ostrominski","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2025081219532729600_pvaf036-B63","first-page":"e43197","article-title":"Metoprolol or verapamil in the management of patients with hypertrophic cardiomyopathy: a systematic review","volume":"15","author":"Taha","year":"2023","journal-title":"Cureus"},{"key":"2025081219532729600_pvaf036-B64","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1161\/CIRCULATIONAHA.123.065017","article-title":"Improved cardiac performance and decreased arrhythmia in hypertrophic cardiomyopathy with non-beta-blocking R-enantiomer carvedilol","volume":"148","author":"Seo","year":"2023","journal-title":"Circulation"},{"key":"2025081219532729600_pvaf036-B65","doi-asserted-by":"crossref","first-page":"185S","DOI":"10.1093\/ajh\/4.2.185S","article-title":"Negative inotropic activity of the calcium antagonists isradipine, nifedipine, diltiazem, and verapamil in diseased human myocardium","volume":"4","author":"Schwinger","year":"1991","journal-title":"Am J Hypertens"},{"key":"2025081219532729600_pvaf036-B66","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1161\/01.HYP.0000013264.41234.24","article-title":"Effects of chronic calcium channel blockade on sympathetic nerve activity in hypertension","volume":"39","author":"Binggeli","year":"2002","journal-title":"Hypertension"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvaf036\/63205468\/pvaf036.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/11\/5\/469\/63205468\/pvaf036.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/11\/5\/469\/63205468\/pvaf036.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T23:53:40Z","timestamp":1755042820000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/11\/5\/469\/8133613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":66,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,16]]},"published-print":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvaf036","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,5,16]]}}}